Urologiia (Moscow, Russia : 1999) · 2025
[Efficacy and Side Effects of Lutetium-177 PSMA-617 in Patients with Castration Resistant Metastatic Prostate Cancer: A Systematic Review and Meta- analysis].
СтатьяСистематический обзорМетаанализАннотация на английскомНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Omar Fahmy Omar Fahmy, Mohd Razaleigh Yusof Mohd Razaleigh Yusof, Mohd Ghani Khairul Asri Mohd Ghani Khairul Asri
Аннотация
BACKGROUND: Progression of metastatic prostate cancer after castration resistance is one of the main challenges in prostate cancer therapy. 177Lu-PSMA-617 has been recently investigated in castration resistant metastatic prostate cancer.
OBJECTIVES: To systematically evaluate the efficacy and safety profile of 177Lu-PSMA- 617.
PATIENTS AND METHODS: A systematic review and meta-analysis was conducted according PRISMA principles. From initial 261 results, 3 randomized controlled trials met our inclusion criteria. The primary outcome of this study was oncological response and side effects. RevMan 5,4 software was applied in this systematic review and meta- analysis.
RESULTS: A total of 1071 patients were included in the pooled analysis. 670 (62,6%) patients received 177Lu-PSMA-617. Progression-free survival was significantly better with a hazard ratio of 0,72 (p= 0,00001). 50%>PSA reduction reported in 75 (63%) vs. 45/121 patients (37,2%) (p=0,0001). Total adverse events recorded in 572 / 627 (91,2%) developed AEs, vs. 204 / 290 (70,3%) (p = 0,00001). Fatigue was reported in 306/647 (47,3%) patients vs 88/310 (28,4%) (p=0,00001). And constipation in 110/549 (20%) vs 24/225 (10,7%) (p=0,003). Both thrombocytopenia and leucopoenia were marginally significantly higher in 114 / 647 (17,6%) vs 19 / 310 (6,1%) (p=0,08) and 81 / 647 (12,5%) vs 13 / 310 (4,2%) (p=0,10), respectively.
CONCLUSION: 177Lu-PSMA-617 results in significant reduction in PSA and improves the progression-free survival. It can cause tolerable side effects, mainly fatigue, constipation, thrombocytopenia and leucopoenia.
OBJECTIVES: To systematically evaluate the efficacy and safety profile of 177Lu-PSMA- 617.
PATIENTS AND METHODS: A systematic review and meta-analysis was conducted according PRISMA principles. From initial 261 results, 3 randomized controlled trials met our inclusion criteria. The primary outcome of this study was oncological response and side effects. RevMan 5,4 software was applied in this systematic review and meta- analysis.
RESULTS: A total of 1071 patients were included in the pooled analysis. 670 (62,6%) patients received 177Lu-PSMA-617. Progression-free survival was significantly better with a hazard ratio of 0,72 (p= 0,00001). 50%>PSA reduction reported in 75 (63%) vs. 45/121 patients (37,2%) (p=0,0001). Total adverse events recorded in 572 / 627 (91,2%) developed AEs, vs. 204 / 290 (70,3%) (p = 0,00001). Fatigue was reported in 306/647 (47,3%) patients vs 88/310 (28,4%) (p=0,00001). And constipation in 110/549 (20%) vs 24/225 (10,7%) (p=0,003). Both thrombocytopenia and leucopoenia were marginally significantly higher in 114 / 647 (17,6%) vs 19 / 310 (6,1%) (p=0,08) and 81 / 647 (12,5%) vs 13 / 310 (4,2%) (p=0,10), respectively.
CONCLUSION: 177Lu-PSMA-617 results in significant reduction in PSA and improves the progression-free survival. It can cause tolerable side effects, mainly fatigue, constipation, thrombocytopenia and leucopoenia.